

List of 22 Research Studies

Abilify Maintena:

1. J. Kane, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 73 (2012): 617-624
2. J. Kane. Aripiprazole once monthly in the acute treatment of schizophrenia: Findings from a 12-week, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 75 (2014): 1254-1260.
3. J. Calabrese, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar 1 disorder. A double-blind, placebo-controlled, 52-week randomized withdrawal study. *J Clin Psychiatry* 78 (2017): 324-331.

Brintellix/Trintellix

4. E. Alvarez, et al. A double-blind, randomized, placebo-controlled, active reference study of LUAA21004 in patients with major depressive disorder. *Int. Journal of Psychopharmacology* 15 (2012):589-600.
5. J. Boulenger, et al. A randomized clinical study of LU AA21004 in the prevention of relapse in patients with major depressive disorder. *J of Psychopharmacology* 26 (2012): 1408-1416.
6. J. Boulenger, et al. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg. a day: a randomized, double-blind, placebo-controlled duloxetine-reference study in the acute treatment of adult patients with major depressive disorder. Jean Philippe Boulenger, *Int. Clinical Psychopharmacology* 29 (2014):138-149.
7. P. Jacobsen, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg. and 20 mg in adults with major depressive disorder. *J. Clin Psychiatry* 76 (2015):575-582.

Rexulti

8. J Kane, et al. "A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. *Schizophrenia Research* 164 (2015):127-135.

9. C. Correll, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. *Am J Psychiatry* 172 (2015): 870-880.
10. C. Correll, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. *Schizophrenia Research* 174 (2016): 82-92.

Vraylar

11. S. Durgam, et al. Cariprazine in acute exacerbation of schizophrenia. A fixed-dose, phase 3, randomized double-blind, placebo- and active-controlled trial. *J. Clin Psychiatry* 76 (2015): e1574-e1582.
12. S. Durgam, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. *Schizophrenia Research* 176 (2016): 264-271.
13. S. Marder, et al. Efficacy of cariprazine across symptoms domains in patients with acute exacerbation of schizophrenia: pooled analyses from 3 phase II/Phase III studies. *Eur Neuropsychopharmacology* 29 (2019): 127-136.
14. S. Durgam, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar 1 depression. *Am J Psychiatry* 173 (2016):271-281.
15. W. Earley, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. *Am J Psychiatry* 176 (2019): 439-448.
16. W. Earley, et al. Efficacy and safety of cariprazine in bipolar 1 depression. *Bipolar Disorders* 22 (2020): 372-384.

Aristada

17. H. Meltzer, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. *J Clin Psychiatry* 76 (2015): 1085-1090.
18. L. Citrome, et al. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the positive and negative syndrome scale—supportive analyses from a phase 3 study. *CNS Spectrums* 23 (2018): 284-290.

Austedo

19. H. Fernandez, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. The ARM-TD study. Hubert Fernandez. *Neurology* 88 (2017): 2003-2010.
20. H. Fernandez, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. *J Neurol Neurosurg Psychiatry* 90 (2019): 1317-1323.

Ingrezza

21. R. Hauser, et al. Kinect 3. A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. *Am J Psychiatry* 174 (2017): 476-484.
22. C. Correll, et al. Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. *J Clin Psychiatry* 80 (2018): 18m12278